Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR18034 for postoperative intercostal nerve block analgesia after thoracoscopic lobectomy
CTR20230022Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2023
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liposomal ropivacaine in postoperative pain (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Area under the pain intensity-time curve during movement or coughing (A-AUC, 0–72 h). Started Jan 2023; status: completed.
02
Drugs
liposomal ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20230022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230022.